The Life Sciences team advised Concert Pharmaceuticals in connection with its financing with BVF Partners L.P. and RA Capital Management, L.P. for gross proceeds of $65 million.
As part of the financing, which consisted of a Securities Purchase Agreement and a Royalty Purchase Agreement, BVF and RA received an aggregate of 16,250,000 common stock equivalents, warrants to purchase up to 8,125,000 common stock equivalents at an exercise price of $5.34 per share and warrants to purchase up to 8,125,000 common stock equivalents at an exercise price of $7.35 per share. The common stock equivalents were issued as shares of common stock or convertible preferred stock.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform).
The Goodwin team was led by John Mutkoski, Yasin Akbari and Della Fok (Corporate), Shane Albright and Paresh Kumar (IP), and Janet Andolina (Tax), with assistance from Brad Weber and Mark Burnett (Opinions) Sarah Ashfaq and Larissa Pinho (Corporate) and Troy Root (Debt Finance).
For more details, read the article in AskTraders.